Clinical Trials
1,006 trialsPhase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
University of Oklahoma
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
CATPCC-01
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC
Fudan University
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
Hunan Cancer Hospital
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
City of Hope Medical Center
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
ASCEND
UNC Lineberger Comprehensive Cancer Center
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
SERPENTINE
Vall d'Hebron Institute of Oncology
QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
TREAT-EC
Rutgers, The State University of New Jersey
PROMPT
University College, London
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
MARACAS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
University of Miami
QNACTH
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Ciusss de L'Est de l'Île de Montréal
Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya
UNC Lineberger Comprehensive Cancer Center
N01-A-PICIT-GT
Peking University People's Hospital
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
University Hospital, Linkoeping
Reiki-Brachy
University of Utah
Topical Curcumin for HPV Related Cervical Disease
Emory University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
DOVE
Yonsei University
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
PapiVax Biotech, Inc.
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
ALEPRO
Universitaire Ziekenhuizen KU Leuven
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
PAM-II
University Medical Center Groningen
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
University of California, San Francisco